The gastrointestinal (GI) tract is the most common primary site of extranodal diffuse large B-cell lymphoma (DLBCL), approximately one-third of extranodal DLBCL occurred in the GI tract. We investigated the clinicopathological features and immunohistochemically-assessed cell-of-origin of 49 GI DLBCL (stomach: 24, small intestine: 10, colon: 15) and also examined the presence of MYD88 L265P as recently this mutation has been frequently identified in ABC-like DLBCL, particularly in extranodal sites.
INTRODUCTION
The gastrointestinal (GI) tract is the most common primary site of extranodal diffuse large B-cell lymphoma (DLBCL). 1 From our consultation files , approximately one-third of extranodal DLBCL occurred in the GI tract, with DLBCL being the most common subtype in the small intestine and large intestine and the second most common subtype in the stomach and duodenum, following mucosa-associated lymphoid tissue (MALT) lymphoma and follicular lymphoma, respectively. intracellular domain of toll-like/IL-1 receptors to form a dimer. This dimer phosphorylates IRAK1 and IRAK4 before activating the NFκB pathway via TRAF6 and TAK1. MYD88
L265P is the most frequent mutation and is known to be a gain of function mutation that contributes to tumor cell growth.
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MYD88 L265P was reported to be frequently identified in ABC/ non-GCB-like DLBCL (21.6%-31.2%) compared with GCB-like DLBCL (6.0%-9.7%). [13] [14] [15] [16] [17] Recent reports have revealed that MYD88 L265P was frequently detected in primary testicular DLBCL (68%-71%), primary central nervous system (CNS) DLBCL (75%-94%), and primary breast DLBCL (58.7%), where the ABC/ non-GCB-like phenotype dominated.
14, [18] [19] [20] In primary GI DLBCL, the frequency of MYD88 L265P and its relationship with clinicopathological features have not been well studied to date. The GI tract, which has its own lymphoid tissues, has immunologically-specific environments where antigen stimuli are fulminant. In the present study, we aimed to investigate the clinicopathological features and immunohistochemically-assessed cell-of-origin and to examine the frequency and clinicopathological relationship of MYD88 L265P with primary GI DLBCL.
MATERIALS AND METHODS
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360 PCR Master MIX (Applied Biosystems, CA, USA). The primer sequences for this study were as follows: MYD88-1F (5′-GTTGAAGACTGGGCTTGTCC-3′), MYD88-6R
(5′-GGTTGGTGTAGTCGCAGACA-3′), and MYD88-7R
(5′-GTGCAGGGGTTGGTGTAGTC-3′). PCR and Sanger sequencing were performed as previously reported.
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Immunohistochemistry
Immunohistochemical analysis was performed on FFPET using Bond-Max Autostainer (Leica Biosystems, Melbourne, Australia), according to the manufacturer's instructions. The primary antibodies used are shown in Table S1 . The cutoff values were set as follows: 80%
for GCET1, FOXP1, and MUM1, and 70% for c-MYC, and 30% for BCL6 and CD10. We classified the cases into ABC-like or GCB-like DLBCL, and non-GCB-like or GCB-like DLBCL, according to Choi's and Hans' algorithms, respectively. 6 Ki-67 labeling index was evaluated by counting the average of 1220 (822-1642) cells in each case using Patholoscope (MITANI CORPORATION, Fukui, Japan).
Statistical analysis
Chi-square test and Fisher's exact test were performed using the Statcel3 (OMS publishing Inc., Saitama, Japan). Statistical significance was defined as P < 0.05.
RESULTS
Characteristics of Patients with GI DLBCL
The clinicopathological characteristics of patients with GI DLBCL are shown in Table 1 and 1) died of DLBCL, whereas nine patients (stomach: 5, small intestine: 3, colon: 1) died of causes other than lymphoma.
Comparison of the clinicopathological characteristics among gastric, small intestinal, and colonic DLBCLs are shown in Table 1 . Females sex (P = 0.041) and elevation in levels of LDH (P = 0.002) and sIL-2R (P = 0.033) were frequently seen in small intestinal DLBCL.
Compared with gastric DLBCL, small intestinal DLBCL more frequently showed anemia (P = 0.031) and elevation of CRP level (P = 0.029), although there was no significant difference when compared with colonic DLBCL.
Histology and Immunophenotype of GI DLBCL
All cases demonstrated diffuse proliferation of large lymphoid cells with CD20+ and CD3−.
The Ki-67 labeling index was 68.3% on average (range, 35%-90%) ( Fig. 1 and Table 2 ). Table 2 ; 35 of 49 cases (71.4%) showed ABC-like phenotype, whereas 14 of 49 cases (28.6%) showed GCB-like phenotype. The ratio of ABC-like/ GCB-like phenotype was 19/5 for the stomach, 7/3 for the small intestine, and 9/6 for the colon.
Detection of MYD88 L265P
MYD88 L265P was detected in only 3 of 49 cases (6.1%) (Fig. 2) ; all of them were primary gastric DLBCL with ABC-like phenotype. Moreover, MYD88 L265P was not detected in primary small intestinal or colonic DLBCL. Comparison of the clinicopathological features between wild type and MYD88 L265P cases of primary gastric DLBCL showed that there was no distinct clinicopathological difference between the two (Table S3 ). In addition, there was no case in present series including 3 MYD88 L265P cases, which had MALT lymphoma or lymphoplasmacytic lymphoma in the background or other sites of DLBCL.
Comparison of MYD88 L265P frequency with Other Extranodal DLBCLs
MYD88 L265P was reported to be frequently detected in extranodal DLBCL where the ABC-like phenotype dominated, such as testis CNS breast and skin. 14, [18] [19] [20] 22 We re-classified GI DLBCL by Hans' algorithm and compared with other organs of the previous studies. As a result, non-GCB-like DLBCL in the GI DLBCL was 49%(24/49) [58%(14/24) in the gastric one, 40%(4/10) in the small intestinal one, and 40%(6/15) in the colonic one]. The frequency of MYD88 L265P in non-GCB like DLBCL was 8.3%, which was significantly rare compared with other extranodal DLBCLs (57.1-100%) (P < 0.001). (Table S4 and Fig. 3) DLBCL, in 75%-94% of primary CNS DLBCL, and in 68%-71% of primary cutaneous DLBCL leg type. 13, 18, 19, 22, 23 Recently, we reported that MYD88 L265P was detected in 58.7%
of primary breast DLBCL. 20 One report mentioned an 11% (2/18) frequency of MYD88 L265P in GI DLBCL, but the percentage of mutation and clinicopathological correlations in each GI organ were unknown. 14 In this study, the frequency of MYD88 L265P was 6.1%, and all mutated cases were gastric DLBCL. Previously, MYD88 L265P was frequently identified in the organs where ABC-like/ non-GCB-like phenotype dominated. On the other hand, GI DLBCL, as we mentioned in the Results, was on the line, half of which(49%) was non-GCB-like phenotype by Hans' algorithm and 71% of which was ABC-like phenotype by Choi's algorithm. At any rate, it is noted that when Hans was applied, the frequency of MYD88 L265P in non-GCB-like DLBCL was also significantly low (P < 0.001) compared with other extranodal DLBCLs. We think that this suggested the uniqueness of the GI DLBCL. (Table S4 and Fig. 3 ) These results suggested that GI DLBCL develops via different pathways of lymphoma genesis compared with DLBCL at other sites wherein MYD88 L265P is frequently detected. The GI tract is known to be always exposed to antigen stimuli; in fact, it is suggested to be an immunologically-specific environment. Although this could partly explain the low mutation rate in this study, some other organ-specific factors might be contributory because MYD88
L265P has been frequently detected in primary cutaneous DLBCL leg type, 22, 23 which has an antigen stimulation that is similar to that on the GI tract. This hypothesis remains to be discussed in the future.
In this study, only three cases had MYD88 L265P and had relatively low tumor burden and low IPI. All patients achieved CR after chemotherapy and remained alive without relapse;
however, there was no distinct clinicopathological factor that indicated a worse prognosis between MYD88 L265P and wild-type cases. In a review of previous studies, there was no consensus about the correlation of MYD88 L265P with the prognosis of DLBCL. It was reported that MYD88 L265P was a prognostic factor for primary cutaneous DLBCL leg type 22, 23 but not for primary CNS DLBCL and primary breast DLBCL. 19, 20 Therefore, the prognostic value of MYD88 L265P may depend on the organ involved in DLBCL. Because L265P is the most frequent mutation site, we examined only L265P in this study. It is possible that mutations of MYD88 other than L265P was seen in GI DLBCL, but this issue needs further study. So far, several kinds of primers and detection methods were used in previous reports. Allele-specific PCR (AS-PCR) was adopted in some papers 14, 18, 21 the primers were different among them. We used the same primers and protocols of our previous study 20 . There is a possibility of difference in MYD88 L265P frequency that is caused by the sensitivity of methods. But as our group reported before 20 , the sensitivity of the AS-PCR for the Sanger sequencing was 92.6%, the specificity was 100%, and then the concordance rate was high between AS-PCR and Sanger sequencing. Therefore, we think that the low prevalence of MYD88 L265P in GI DLBCL could be attributed to the feature of GI DLBCL rather than the detection protocol itself. However, it needs to be assessed by other methods in the future.
In primary GI tract DLBCL, the frequency of ABC-like/ non-GCB-like DLBCL was reported to be 42%-73% in the stomach, 6%-14% in the small intestine, and 57% in the colon. [7] [8] [9] 11 In this study, the frequency of ABC-like DLBCL was 79% (19/24) and 58% (14/24) in the stomach, 70% (7/10) and 40% (4/10) in the small intestine, and 60% (9/15) and 40% (6/15) in the colon by Choi's and Hans' algorithm, respectively. In this study, the frequency of ABC-like/ non-GCB-like DLBCL in the small intestine was higher than that in previous reports. The proportion of non-GCB-like phenotype in small intestinal DLBCL was reported as 6% and 14%, 9,11 both of which were according to Hans' algorithm. 5 The discrepancy in the percentage of ABC-like phenotype between previous reports and our study could be caused by differences in the positivity of CD10 among these studies. The positivity of CD10 was reported by previous studies to be 75%-86%; 9,11 however, in this study, only 40% was positive for CD10. This may be considered as the most significant factor for the higher ABC-like DLBCL cases in this study than in previous reports.
When focusing on the primary site, primary small intestinal DLBCL showed significant LDH These need to be kept in mind in the clinical practice.
In conclusion, GI DLBCL had different clinicopathological features according to the primary site especially in small intestine. And MYD88 L265P had little involvement in GI DLBCL compared with other extranodal DLBCLs, suggesting that its pathogenesis might be different from that of organs with a high frequency of MYD88 L265P. A large cohort study is needed to confirm our results, and further molecular analysis might clarify the specific nature of GI DLBCL.
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Table S2
The clinical information of gastrointestinal DLBCL cases. The percentage of non-GCB-like phenotype in extranodal DLBCLs was shown. White column shows wild type cases and black column shows MYD88 L265P cases. MYD88
L265P in non-GCB-like DLBCL was significantly rare in gastrointestinal DLBCL compared with other extranodal DLBCLs (P < 0.001). * the ratio of MYD88 L265P in non-GCB-like 
